HKDC1 Knockout MDA-MB-231 Cell Line

The HKDC1 Knockout MDA-MB-231 Cell Line is a CRISPR/Cas9-edited loss-of-function cell model that enables precise investigation of hexokinase domain containing 1 (HKDC1) function in a human triple-negative breast cancer (TNBC) context. Derived from the widely utilized MDA-MB-231 host cell line, this knockout product is engineered to disrupt endogenous HKDC1 gene expression, providing a stable and reproducible platform for probing the metabolic and signaling roles of this hexokinase. The cell line is supplied as a frozen vial of edited cells, ready for expansion and application in functional genomics, cancer metabolism, and drug development studies. Researchers can employ this tool to dissect HKDC1-dependent pathways without transient silencing artifacts, thereby generating robust and biologically relevant data.

The parental MDA-MB-231 cell line originates from the pleural effusion of a patient with metastatic breast adenocarcinoma and represents a mesenchymal-like, basal-like TNBC subtype. These cells harbor a TP53 mutation and exhibit aggressive characteristics in vitro and in vivo, including high proliferative rate, invasiveness, and distinct metabolic dependencies. MDA-MB-231 cells are extensively employed as a model system for studying the molecular underpinnings of TNBC, particularly the interplay between oncogenic signaling and metabolic reprogramming. Their reliance on glycolysis and glutaminolysis for energy and biosynthesis makes them particularly suitable for interrogating the function of glucose-metabolizing enzymes such as HKDC1.

HKDC1 encodes a hexokinase that catalyzes the phosphorylation of glucose to glucose-6-phosphate, a critical rate-limiting step that channels glucose into glycolysis and the pentose phosphate pathway. The enzyme is transcriptionally regulated by hypoxia-inducible factor 1-alpha (HIF1A) and the oncogene MYC, and its activity is influenced by glucose availability. HKDC1 physically interacts with the voltage-dependent anion channel 1 (VDAC1) on the outer mitochondrial membrane, coupling glycolytic flux to mitochondrial metabolism. Downstream, HKDC1 activity affects the production of glycolytic intermediates and controls flux through parallel metabolic branches, including the pentose phosphate pathway. Key pathway components functionally linked to HKDC1 in breast cancer cells include the glucose transporter GLUT1, hexokinase 2 (HK2), the glycolytic regulators PFKFB3 and PKM2, lactate dehydrogenase A (LDHA), and the mitochondrial pyruvate carrier MPC1. The interplay of these factors positions HKDC1 as a nexus between extracellular nutrient sensing, glycolytic throughput, and mitochondrial respiration.

In the MDA-MB-231 background, HKDC1 knockout is anticipated to impair early glycolytic steps, reducing glucose-6-phosphate pools and compromising metabolic flexibility. TNBC cells often exhibit elevated aerobic glycolysis (Warburg effect), and HKDC1 likely contributes to sustaining this phenotype. By abolishing HKDC1 function, this model allows researchers to study how loss of one hexokinase isoform reshapes the metabolic network, potentially revealing compensatory roles of HK2 or adaptations in glutamine metabolism. Given its proposed tumor-suppressive roles in certain contexts, HKDC1 ablation may paradoxically alter proliferative and invasive capacities, offering a nuanced system to examine context-dependent metabolic vulnerabilities. The knockout cell line thus serves as a unique reagent to parse HKDC1-specific contributions to TNBC metabolic reprogramming, redox balance, and anabolic synthesis.

This cell line is ideally suited for a broad range of functional analyses, including metabolic flux assays using Seahorse analyzers, glucose uptake measurements, and immunoblotting or RT-qPCR to verify knockout efficiency and downstream effects. Researchers can investigate the impact of HKDC1 loss on cell proliferation, migration, and apoptosis, as well as response to metabolic inhibitors targeting glycolysis or mitochondrial function. The model further enables dissection of HKDC1-dependent signaling networks through phosphoproteomics and metabolite profiling. For customized inquiries or additional technical information regarding the HKDC1 Knockout MDA-MB-231 Cell Line, please contact Ascent Research.